Oxygen Biotherapeutics Inc.

EANS-Adhoc: Oxygen Biotherapeutics and Aurum Biosciences Sign Letter of Intent to Explore the Use of Oxycyte® PFC for Imaging and Therapeutic Intervention of Acute Ischemic Stroke

--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
Research & Development

25.07.2011

MORRISVILLE, NC, July 25, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX
Swiss Exchange: OXBT) and privately held Aurum Biosciences Ltd. of Glasgow,
Scotland,  today announced they signed a Letter of Intent (LOI) to conduct
preclinical research for imaging and therapeutic intervention of acute ischemic
stroke.  The research will be conducted by Aurum using Oxygen´s proprietary
Oxycyte® PFC (perfluorocarbon) emulsion in combination with Aurum´s proprietary
Glasgow Oxygen Level Dependent (GOLD) Magnetic Resonance Imaging techniques.  

The intent of this research is to better delineate which tissue has been damaged
from a stroke, and to determine the effectiveness of the treatment being
provided to the model. Per the LOI, Aurum will seek funding for this research.

"Stroke is the third leading cause of death in the world and better treatments
and diagnostics will go a long way toward improving that statistic," said Chris
Stern, Chairman and Chief Executive Officer of Oxygen.  "We are pleased to
collaborate with Aurum on this important research initiative, which clearly is
in line with our strategic vision."

"Aurum is looking forward to working with Oxygen Biotherapeutics on the
development of a novel stroke product," said Gerry McGettigan, Chief Executive
Officer of Aurum. "Our combined technology and stroke management product may for
the first time allow us to accurately diagnose acute stroke and treat a majority
of the patients effectively."

end of ad-hoc-announcement
================================================================================
U.S. and U.K. Stroke Statistics

An ischemic stroke occurs when a blood vessel that carries oxygen and nutrients
to the brain is blocked by a clot. When that happens, part of the brain cannot
get the blood and, therefore, the oxygen it needs, so it starts to die. 
According to the American Stroke Association, approximately 795,000 Americans
each year suffer a new or recurrent stroke. That means, on average, a stroke
occurs every 40 seconds. Stroke kills more than 137,000 people a year in the
United States alone and is the third leading cause of death behind diseases of
the heart and cancer. On average, every 4 minutes someone dies of stroke. About
40 percent of stroke deaths occur in males, and 60 percent in females. According
to The Stroke Association, an estimated 150,000 people have a stroke in the U.K
each year, accounting for around 53,000 deaths annually.  Stroke is the third
most common cause of death in England and Wales, after heart disease and cancer.
 Stroke accounts for 9 per cent of all deaths in men and 13 per cent of deaths
in women in the U.K. 


About Aurum Biosciences, Ltd.

Aurum Biosciences is dedicated to protecting lives through the use of its
proprietary imaging technology and novel approach to therapy in areas such as
stroke, cardiovascular disease, oncology and epilepsy. The technology behind
Aurum’s products has come from researchers at the Southern General Hospital in
Glasgow and The University of Glasgow, both leaders in the fields of
neurological, cardiovascular and oncological disease research. Aurum is
currently engaging with investors for the funding of research and development
studies to complement the extremely promising data generated to date. 


About Oxygen Biotherapeutics, Inc.

Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is developing
medical and cosmetic products that efficiently deliver oxygen to tissues in the
body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier product called Oxycyte that is being formulated for both
intravenous and topical delivery. The company has commercialized its DERMACYTE®
line of oxygen-rich skin care products. In addition, the company is focused on
perfluorocarbon-based oxygen carriers for use in traumatic brain injury,
decompression sickness, personal care, and topical wound healing. More
information is available at www.oxybiomed.com or www.buydermacyte.com.



Caution Regarding Forward-Looking Statements 
This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company's judgment as of
the date of this release. These statements include the management transition,
and expansion of research and development of the Oxycyte product line, including
and the timing of the introduction of those new products.  The forward-looking
statements are subject to a number of risks and uncertainties including matters
beyond the company’s control that could lead to delays in new product
introductions and customer acceptance of these new products, and other risks and
uncertainties as described in our filings with the Securities and Exchange
Commission, including in the current report on Form 10-Q filed on September 9,
2010. The company disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release. This caution is made
under the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995.



Further inquiry note:
Für weitere Auskünfte wenden Sie sich an:

Ellen Corliss	
Vice President, Corporate Communications 	
& Investor Relations			
Oxygen Biotherapeutics, Inc	
One Copley Pkwy, Suite 490	
Morrisville, NC 27560		
Direct Telephone: +1 919 855 2112			
Direct Fax: +1 919 806 4417	
Email: e.corliss@oxybiomed.com 


Dr. Chris Stern
Chairman of the Board & CEO			
Oxygen Biotherapeutics, Inc 
One Copley Pkwy, Suite 490
Morrisville, NC 27560	
Direct Tel.: +1 919 855 2151	
Direct Fax: +1 419 710 8764
Email: c.stern@oxybiomed.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      Oxygen Biotherapeutics Inc.
             2530 Meridian Pkwy 
             US-27713 Durham, NC
phone:       +1(919)7607606
FAX:         +1(419)7108764
mail:     c.stern@oxybiomed.com
WWW:      www.oxybiomed.com
sector:      Biotechnology
ISIN:        US69207P2092
indexes:     SSIRT
stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange 
language:   English
 



Weitere Meldungen: Oxygen Biotherapeutics Inc.

Das könnte Sie auch interessieren: